Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Neuronetics Inc (STIM)

Neuronetics Inc (STIM)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 78,068
  • Shares Outstanding, K 18,632
  • Annual Sales, $ 52,780 K
  • Annual Income, $ -24,100 K
  • 60-Month Beta 0.68
  • Price/Sales 1.25
  • Price/Cash Flow N/A
  • Price/Book 1.45

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate -0.45
  • Number of Estimates 2
  • High Estimate -0.42
  • Low Estimate -0.48
  • Prior Year -0.35
  • Growth Rate Est. (year over year) -28.57%

Price Performance

See More
Period Period Low Period High Performance
1-Month
4.02 +4.23%
on 01/14/20
4.66 -10.01%
on 01/02/20
-0.31 (-6.89%)
since 12/24/19
3-Month
3.96 +5.81%
on 11/27/19
9.10 -53.96%
on 10/28/19
-4.44 (-51.45%)
since 10/24/19
52-Week
3.96 +5.81%
on 11/27/19
18.45 -77.29%
on 02/15/19
-9.79 (-70.03%)
since 01/24/19

Most Recent Stories

More News
Gastro Esophageal Reflux Disease Drug and Devices Market 2019 Global Overview, Latest Technologies, Business Strategy, Key Vendors, Segments, Demands, Growth Factors, Size, Share by Forecast to 2025

A recent report provides crucial insights along with application based and forecast information in the Global Gastro Esophageal Reflux Disease Drug and Devices Market. The report provides a comprehensive...

AZN : 49.28 (-1.83%)
BSX : 43.21 (-0.83%)
CEMP : 2.33 (+1.30%)
STIM : 4.19 (-1.87%)
GSK : 47.23 (-1.23%)
IRWD : 12.37 (-3.59%)
MDGS : 1.87 (unch)
MDT : 119.26 (-1.41%)
MRK : 85.98 (-2.91%)
NVS : 93.87 (-1.11%)
PFE : 39.82 (-2.19%)
TKPYY : 16.5900 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Neuronetics Appoints Andrew Macan As Senior Vice President, General Counsel, Chief Compliance Officer and Corporate Secretary

Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric...

STIM : 4.19 (-1.87%)
Gastro Esophageal Reflux Disease Drug and Devices Market With Moderate CAGR in Forecast Period 2019 to 2026

The research includes a comprehensive analysis of market outlook, methodology and political-economic impacts. The report complies with estimated market size, share, product, revenue, and rate of advancement...

AZN : 49.28 (-1.83%)
BSX : 43.21 (-0.83%)
CEMP : 2.33 (+1.30%)
STIM : 4.19 (-1.87%)
GSK : 47.23 (-1.23%)
IRWD : 12.37 (-3.59%)
MDGS : 1.87 (unch)
MDT : 119.26 (-1.41%)
MRK : 85.98 (-2.91%)
NVS : 93.87 (-1.11%)
PFE : 39.82 (-2.19%)
TKPYY : 16.5900 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Neuronetics to Present at the 31st Annual Piper Jaffray Healthcare Conference

Neuronetics, Inc. (NASDAQ:STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric...

STIM : 4.19 (-1.87%)
Dare Bioscience Closes Previously Announced Acquisition of Microchips Biotech with a First-in-Class Wireless, User-Controlled Drug Delivery Platform

Dare Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced the closing of the previously announced acquisition by merger of privately-held Microchips Biotech, Inc. As...

DARE : 1.27 (-7.97%)
ANIK : 43.89 (-4.52%)
STIM : 4.19 (-1.87%)
Neuronetics® to Present New Depression Research at 15th Annual Neuroscience Education Institute Congress

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric...

STIM : 4.19 (-1.87%)
Neuronetics (STIM) Reports Q3 Loss, Lags Revenue Estimates

Neuronetics (STIM) delivered earnings and revenue surprises of 9.76% and -0.78%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

STIM : 4.19 (-1.87%)
Neuronetics: 3Q Earnings Snapshot

MALVERN, Pa. (AP) _ Neuronetics Inc. (STIM) on Tuesday reported a loss of $6.9 million in its third quarter.

STIM : 4.19 (-1.87%)
Neuronetics Reports Third Quarter 2019 Financial and Operating Results

Neuronetics, Inc. (NASDAQ: STIM), a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric...

STIM : 4.19 (-1.87%)
Neuronetics(R) Announces Appointment of Sheryl Conley to its Board of Directors

Neuronetics, Inc. (NASDAQ: STIM), a commercial-stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric...

STIM : 4.19 (-1.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade STIM with:

Business Summary

Neuronetics, Inc. is a commercial-stage medical device company. It focused on designing, developing, and marketing products for patients who suffer from psychiatric disorders. NeuroStar Advanced Therapy System(R), is the transcranial magnetic stimulation treatment for depressive disorder. Neuronetics,...

See More

Key Turning Points

2nd Resistance Point 4.39
1st Resistance Point 4.29
Last Price 4.19
1st Support Level 4.12
2nd Support Level 4.05

See More

52-Week High 18.45
Fibonacci 61.8% 12.91
Fibonacci 50% 11.20
Fibonacci 38.2% 9.50
Last Price 4.19
52-Week Low 3.96

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar